Indegene Limited (NSE:INDGN)
 536.80
 -15.25 (-2.76%)
  Oct 31, 2025, 12:30 PM IST
Indegene Revenue
Indegene had revenue of 7.61B INR in the quarter ending June 30, 2025, with 12.46% growth. This brings the company's revenue in the last twelve months to 29.24B, up 9.97% year-over-year. In the fiscal year ending March 31, 2025, Indegene had annual revenue of 28.39B with 9.64% growth.
Revenue (ttm) 
 29.24B
Revenue Growth 
 +9.97%
P/S Ratio 
 4.53
Revenue / Employee 
 7.03M
Employees 
 4,158
Market Cap 
132.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Mar 31, 2025 | 28.39B | 2.50B | 9.64% | 
| Mar 31, 2024 | 25.90B | 2.84B | 12.29% | 
| Mar 31, 2023 | 23.06B | 6.41B | 38.54% | 
| Mar 31, 2022 | 16.65B | 6.84B | 69.76% | 
| Mar 31, 2021 | 9.81B | 3.37B | 52.36% | 
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Sun Pharmaceutical Industries | 537.77B | 
| Aurobindo Pharma | 320.25B | 
| Cipla | 274.80B | 
| Zydus Lifesciences | 236.08B | 
| Apollo Hospitals Enterprise | 225.51B | 
| Glenmark Pharmaceuticals | 134.56B | 
| Alkem Laboratories | 133.04B | 
| Mankind Pharma | 129.10B |